Adherence of human prostate carcinoma (PC 3, DU 145), bladder (647 V, J 82) carcinoma and melanoma (RPMI-8252) cell lines to plastic and bovine endothelial monolayers (BEM) was tested in the presence of 0.5, 1, 5, 10, 20 IU of low-molecular-weight heparin (LMWH), unfractionated heparin (UFH) or saline as a control. Culture medium was supplemented either with 5% fetal calf serum or with human plasma. Floating tumor cells were counted after 2,4,24 h of culture in microtiter plates without BEM and after 1.5,3 and 24 h of culture on BEM. Twenty IU of LMWH increased the numbers of bladder carcinoma cells adhering to BEM as did 20 IU of UFH in cultures of DU 145 prostate carcinoma and RPMI-8252 melanoma cells. LMWH obviously does not prevent human prostate and bladder carcinoma and melanoma cells from adhering to BEM more effectively than UFH. The in vivo effect of UFH and perhaps also LMWH that hinders intravenous tumor cell colonization in blood vessels obviously does not depend on the interaction with endothelial cells alone.

Keywords:
Low-Molecular-weight heparin, Unfractionated heparin, Metastases, Human prostate carcinoma, Human bladder carcinoma, Melanoma
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.